Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...

Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.18 per share, missing the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.19 per share a year ago.

FORTREA ($FTRE) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of $0.18 per share, missing estimates of $0.37 by $0.19. The ...

Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...

(RTTNews) - Below are the earnings highlights for Fortrea Holdings Inc. (FTRE): Earnings ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...

$FTRE insiders have traded $FTRE stock on the open market 3 times in the past 6 months. Of those trades, 0 have been purchases and 3 have been sales. We have seen 115 ...

DURHAM, N.C., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that it will appoint Erin L. Russell, a financial ...

Learn more and get involved at Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large ...

Shares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...

Fortrea, a global contract research organization, has announced the appointment of Erin L. Russell as an independent member of its Board of Directors, effective immediately before the next board ...